Abstract: Objective To investigate effect of nucleos(t)ide analogues (NA) treatment on prognosis of patients with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC). Methods A total of 532 patients with CHB-related HCC in Shanghai Ruijin Hospital from January 2008 to November 2015 were retrospectively analyzed, whose baseline characteristics, NA treatment condition, Barcelona Clinic Liver Cancer (BCLC) scores and liver function were recorded. Patients were divided into three groups, including sustained NA treatment group, post-HCC NA treatment group and NA treatment-naïve group. Prognosis of the three groups was analyzed and compared. Results In NA treatment-naïve group, average levels of serum alpha fetoprotein, alanine aminotransferase, aspartate aminotransferase and direct bilirubin were 3.4-fold (223.3 ng/mL vs. 64.77 ng/mL, P<0.01), 1.4-fold (44 U/L vs. 32 U/L, P<0.01), 1.5-fold (54 U/L vs. 35 U/L, P<0.01) and 1.4-fold (5.4 ng/mL vs. 4 ng/mL, P<0.05) of those in NA treatment group, respectively. According to the BCLC staging system, proportion of patients with stage A or B in NA treatment group (72.03%) was higher than that in NA treatment-naïve group (46.38%). During the follow-up, survival in sustained NA treatment group was significantly longer than that in post-HCC NA treatment group or NA treatment-naïve group (P<0.05). Conclusion NA treatment for CHB-related HCC patients may alleviate disease severity and prolong life survival.

Key words: Nucleos(t)ide analogues, Hepatocellular carcinoma, Prognosis